EGFR and glioblastoma: As a result, besides previously reported lower mutational rates of IDH130 (LGG vs GBM: 76% vs 5%), GBM patients showed lower mutational rates of CIC (LGG vs GBM: 41% vs 11%), higher mutational rates of EGFR (LGG vs GBM: 4% vs 13%), and higher amplification frequencies of locus 7p11.2, 19q13.2 (Fig. 2A).